STOCKHOLM, Oct. 30, 2024 /PRNewswire/ — Sobi® (STO: SOBI) today announced that new research showing the effect of emapalumab in patients with macrophage activation syndrome (MAS) in Still’s disease, including systemic juvenile idiopathic arthritis (sJIA) […]
Tag: Swedish Orphan Biovitrum AB
New data for emapalumab in the treatment of macrophage activation syndrome to be presented at the ACR conference
STOCKHOLM, Oct. 30, 2024 /PRNewswire/ — Sobi® (STO: SOBI) today announced that new research showing the effect of emapalumab in patients with macrophage activation syndrome (MAS) in Still’s disease, including systemic juvenile idiopathic arthritis (sJIA) […]
Pivotal VALIANT results presented at Kidney Week show pegcetacoplan treatment effect in patients with C3G / primary IC-MPGN
Statistically significant 68% (p<0.0001) proteinuria reduction compared to placebo, with reduction observed as early as Week 4 All secondary endpoints favoured treatment with pegcetacoplan, including: – Stabilised eGFR, a key measure of kidney function– 71% of patients achieved […]
Strong growth and significant pipeline momentum
STOCKHOLM, Oct. 24, 2024 /PRNewswire/ — Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the third quarter 2024 Third Quarter 2024 Total revenue increased 33 per cent, 39 per cent at constant […]
Sobi has completed issues of class C shares
STOCKHOLM, Aug. 29, 2024 /PRNewswire/ — The Annual General Meeting of Swedish Orphan Biovitrum AB (publ) (Sobi®) on 14 May 2024 resolved on directed issues of redeemable and convertible class C shares and to authorise the […]
